The emerging role of the PI3-K-Akt pathway in prostate cancer progression

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 2, 2005, Pages 108-118

  Li, L ^a   Ittmann, M M ^a   Ayala, G ^a   Tsai, M J ^a   Amato, R J ^a   Wheeler, T M ^a   Miles, B J ^a   Kadmon, D ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Akt; Biomarker; Caveolin 1; Oncogenic signaling; Prostate cancer; Target; Therapeutic

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BIOLOGICAL MARKER; EVEROLIMUS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS; WORTMANNIN; AKT1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CLINICAL STUDY; CLINICAL TRIAL; DRUG POTENTIATION; GENE CONTROL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; BIOSYNTHESIS; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 23944523430     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500776     Document Type: Review

References (130)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
2. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
3. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395.
4. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003; 115: 145-167.
5. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983-10985.
6. Vivaneo I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
7. Staal SP, Hartley JW. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med 1988; 167: 1259-1264.
8. Leslie NR, Biondi RM, Alessi DR. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem Rev 2001; 101: 2365-2380.
9. Alessi DR et al. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 1996; 399: 333-338.
10. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem Sci 2001; 26: 657-664.
11. Tan C., et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004; 5: 79-90.
12. Troussard AA et al. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 2003; 278: 22374-22378.
13. Di Cristofano A, Pandolfi PP The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
14. Dahia PL. PTEN, a unique tumor-suppressor gene. Endocr Relat Cancer 2000; 7: 115-129.
15. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-4245.
16. Leslie NR, Downes CE PTEN: The down side of PI 3-kinase signalling. Cell Signal 2002; 14: 285-295.
17. Cohen PT. Protein phosphatase 1 - targeted in many directions. J Cell Sci 2002; 115: 241-256.
18. Janssens V, Goris J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353: 417-439.
19. Schonthal AH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett 2001; 170: 1-13.
20. Davies MA et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999; 59: 2551-2556.
21. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999; 24: 186-191.
22. Resjo S., et al. Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes. Cell Signal 2002; 14: 231-238.
23. Ivaska J et al. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol Cell Biol 2002; 22: 1352-1359.
24. Yellaturu CR, Bhanoori M, Neeli I, Rao GN. N-ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A. J Biol Chem 2002; 277: 40148-40155.
25. Teruel T, Hernandez R, Lorenzo M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001; 50: 2563-2571.
26. Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C. A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 2001; 50: 2210-2218.
27. Davidson B., et al. Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study. Gynecol Oncol 2001; 81: 166-171.
28. Fine SW, Lisanti MP, Galbiati F, Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 2001; 115: 719-724.
29. Goh M et al. Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia 2001; 3: 331-338.
30. Ho CC et al. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002; 161: 1647-1656.
31. Hu YC et al. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: Overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 2001; 7: 3519-3525.
32. Ito Y et al. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer 2002; 86: 912-916.
33. Kato K et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002; 94: 929-933.
34. Podar K et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 2003; 278: 5794-5801.
35. Rajjayabun PH et al. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001; 58: 811-814.
36. Suzuoki M et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002; 87: 1140-1144.
37. Tso CL et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000; 6: 220-233.
38. Wu D et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002; 62: 2423-2429.
39. Yang CP et al. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 1998; 439: 368-372.
40. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression m clinically confined human prostate cancer: A novel prognostic marker. Cancer Res 1999; 59: 5719-5723.
41. Li L et al. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23: 9389-9404.
42. Couet J et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 272: 6525-6533.
43. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003 4: 257-262.
44. Obata T et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 2000; 275: 36108-36115.
45. Brunet A et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 1999; 96: 857-868.
46. Datta SR et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
47. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001; 20: 7779-7786.
48. Cardone MH et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
49. Chrivia JC et al. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365: 855-859.
50. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546-5556.
51. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
52. Grimes CA Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001 65: 391-426.
53. Kim AH et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21: 893-901.
54. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598-11603.
55. Tanno S et al. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001; 61: 589-593.
56. Thant AA et al. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis 2000; 18: 423-428.
57. Chan J, Bayliss PE, Wood JM, Roberts TM. Dissection of angiogemc signaling in zebrafish using a chemical genetic approach. Cancer Cell 2002; 1: 257-267.
58. Navarro D et al. Transition to androgen-independence in prostate cancer J Steroid Biochem Mol Biol 2002; 81: 191.
59. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001-3015.
60. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-7205.
61. Wen Y et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-6845.
62. Gioeli D et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002; 277: 29304-29314.
63. Lu ML et al. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001; 276: 13442-13451.
64. Culig Z et al. Androgen receptors in prostate cancer. J Urol 2003; 170: 1363-1369.
65. Cronauer MV et al. The androgen receptor in hormone-refractory prostate cancer: Relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol 2003; 23: 1095-1102.
66. Gelmann EE Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001-3015.
67. Yeh S et al. Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Keio J Med 1999; 48: 87-92.
68. Gnanapragasam VJ et al. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001; 85: 1928-1936.
69. Zhou G et al. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 2003; 23: 7742-7755.
70. Zhou BP, Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol 2002; 29: 62-70.
71. Viglietto G et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) bay PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136-1144.
72. Graft JR et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000; 275: 24500-24505
73. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348.
74. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
75. Altiok S et al. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem 1999; 274: 32274-32278.
76. Dimmeler S et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.
77. Fulton D et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
78. Nakatani K et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999; 274: 21528-21532.
79. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003; 9: 5271-5281.
80. Bellacosa A et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 280-285.
81. Cheng JQ et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-9271.
82. Cheng JQ et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-3641.
83. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84: 5034-5037.
84. Ringel MD et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001; 61: 6105-6111.
85. Sun M et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-437.
86. Liao Y et al. Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer 2003; 107: 676-680.
87. Shayesteh L et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102.
88. Philp AJ et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 7426-7429.
89. Mass RD. The HER receptor family: A rich target for therapeutic development. Int J Radiat Oncol Biol Phys 2004; 58: 932-940.
90. Agus DB et al. A potential role for activated HER-2 in prostate cancer. Semin Oncol 2000; 27: 7643, discussion 92-100.
91. Roskoski Jr R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1-11.
92. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58: 903-913.
93. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003; 28: 145-153.
94. Ittmann MM. Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol Rep 1998; 5: 1329-1335.
95. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: A tumor-suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922-1932.
96. Dong JT. Chromosomal deletions and tumor-suppressor genes in prostate cancer. Cancer Metastasis Rev 2001; 20: 173-193.
97. Latini JM et al. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions. J Urol 2001; 166: 1931-1936.
98. Rubin MA et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 2000; 31: 504-508.
99. Gray IC et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 1998; 78: 1296-1300.
100. Pesche S et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998; 16: 2879-2883.
101. Feilotter HE et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998; 16: 1743-1748.
102. Dong JT, Li CL, Sipe TW, Frierson Jr HF. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 2001; 7: 304-308.
103. Muller M, Rink K, Krause H, Miller K. PTEN/MMAC1 mutations in prostate cancer. Prostate Cancer Prostatic Dis 2000; 3: S32.
104. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 1998; 17: 401-409.
105. Whang YE et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95: 5246-5250.
106. Wang S et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
107. Yang G et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8: 3419-3426.
108. McMenamin ME et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-4296.
109. Wang SS et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998; 282: 284-287.
110. Calin GA et al. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the sefine-threonine phosphatase 2A in human neoplasms. Oncogene 2000; 19: 1191-1195.
111. Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001; 20: 1892-1899.
112. Ruediger R, Pham HT, Walter G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 2001; 20: 10-15.
113. Deichmann M et al. The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Res 2001; 11: 577-585.
114. Tamrakar S, Rubin E, Ludlow JW. Role of pRB dephosphorylation in cell cycle regulation. Front Biosci 2000; 5: D121-D137.
115. Takakura S et al. Genetic alterations and expression of the protein phosphatase 1 genes in human cancers. Int J Oncol 2001; 18: 817-824.
116. Kohno T et al. Alterations of the PPP1R3 gene in human cancer. Cancer Res 1999; 59: 4170-4174.
117. Ayala G et al. High levels of phosphorylated form of Akt-1 in prostate cancer and nonneoplastic tissues are strong predictors of biochemical recurrence. Clinic Cancer Res 2004; 10: 6572-6578.
118. Hu L et al. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-1092.
119. Eaton SR et al. Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity. J Med Chem 1998; 41: 4329-342.
120. Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 2003; 125: 1144-1145.
121. Thomas CC, Deak M, Alessi DR, van Aalten DM. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphalidylinositol (3,4,5)-trisphosphate. Curr Biol 2002; 12: 1256-1262.
122. Lawlor MA, Alessi DR. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903-2910.
123. Tahir SA et al. Development of an immunoassay for serum caveolin-l: A novel biomarker for prostate cancer. Clin Cancer Res 2003; 9: 3653-3659.
124. Tahir SA et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-3885.
125. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-377.
126. Yu K et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258.
127. Neshat MS et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-10319.
128. Podsypanina K et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98: 10320-10325.
129. Dudkin L et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001; 7: 1758-1764.
130. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. Kidney Int 2001; 59: 3-16.